# A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients

> **NCT02672540** · PHASE2 · COMPLETED · sponsor: **Prolong Pharmaceuticals** · enrollment: 34 (actual)

## Conditions studied

- Anemia, Sickle Cell

## Interventions

- **DRUG:** SANGUINATE 320 mg/kg
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT02672540
- **Lead sponsor:** Prolong Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2017-05-31
- **Final completion:** 2017-05-31
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2018-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02672540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02672540, "A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02672540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*